Forskolin for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Forskolin for Health & Longevity

Created on 08/14/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A plant compound that raises a messenger inside cells. Its best-supported human effect is further lowering of pressure inside the eye when added to glaucoma treatment; fat-loss trials disagree. Against that sit a common gut effect, faster drug breakdown in the liver, and animal liver stress from the root extract. Much favourable literature comes from those who sell it. (Full Review)

Protocol

Standard oral protocol
250 mg twice daily
Root extract standardised to 10% forskolin, giving 25 mg forskolin per dose; the regimen used in all three body-composition trials
Eye-pressure protocol
Two tablets daily
Combination supplement of Coleus forskohlii root extract plus rutin, taken alongside — not instead of — prescribed drops
Time of day
Morning and evening
Split dosing was used in all oral trials; an empty stomach favours absorption, but food is the practical override against loose stools
Time to effect
Eye pressure
Within 1 week
Reduction appeared within one week of starting the oral supplement
Body composition
12 weeks
Measured only at 12 weeks, so no earlier readout is documented
Fasting insulin
12 weeks
Measured only at 12 weeks; if the endpoint has not shifted by then, no later response is expected

Benefits

Contraindications
  • Pregnancy, breastfeeding, or actively trying to conceive
  • Polycystic kidney disease, any stage (including asymptomatic gene carriers)
  • Bleeding disorders, or planned surgery within 14 days
  • Symptomatic low blood pressure (seated systolic below 100 mmHg) or untreated orthostatic hypotension
  • Active peptic ulcer disease or uncontrolled reflux oesophagitis
  • Active liver disease, or liver enzymes above twice the upper limit of normal
  • Warfarin users and transplant recipients on ciclosporin or tacrolimus
  • Unstable arrhythmia or a resting heart rate above 100 beats per minute
    •
Key Interactions
  • Anticoagulants (warfarin, apixaban, rivaroxaban)
  • Antiplatelet agents (aspirin, clopidogrel, ticagrelor)
  • Antihypertensives (amlodipine, lisinopril, losartan) and nitrates
  • Drugs cleared by CYP3A4 with a narrow safe dose range (tacrolimus, ciclosporin, simvastatin, some antiretrovirals)
  • Acetaminophen and other liver-activated drugs
  • Diabetes medications (metformin, insulin, sulfonylureas)
  • Thyroid medications (levothyroxine, liothyronine, carbimazole)
  • Over-the-counter medicines (aspirin and ibuprofen-type painkillers, famotidine, omeprazole, pseudoephedrine)
  • Supplement interactions (garlic, hibiscus, magnesium, beetroot nitrate, fish oil, ginkgo, vitamin E, nattokinase, curcumin, vitamin C)
  • Other interventions (procedures with bleeding risk, therapeutic hypotension in surgery, yohimbine, caffeine)

Risk & Side Effects

  • High: Diarrhoea and other gastrointestinal effects
    •
  • Medium: Induction of drug-metabolising enzymes and loss of drug effect; blood-pressure lowering, flushing and rapid heart rate
  • Low: Liver enzyme elevation and fat accumulation in the liver; increased bleeding tendency from platelet inhibition; eye redness and irritation with topical use
  • Speculative: Accelerated cyst growth in polycystic kidney disease; reproductive and pregnancy harm; aggravation of reflux or peptic ulcer; thyroid and steroid hormone disruption

Monitoring

Marker Target Why
ALT Under 25 U/L (men), under 20 U/L (women) Earliest signal of extract-driven liver stress
AST Under 25 U/L Confirms an ALT rise comes from the liver
ALP 45–80 U/L Detects bile-flow rather than cell-injury patterns
GGT Under 20 U/L Separates liver from bone causes of a raised ALP
Fasting insulin 2–5 µIU/mL The endpoint that improved in the one positive metabolic trial
HOMA-IR Under 1.0 Tracks the insulin-sensitivity claim directly
Fasting glucose 75–86 mg/dL Guards against the opposite effect of raised cAMP on liver glucose output
Blood pressure, seated and standing 105–120 / 65–80 mmHg Catches additive hypotension with medication
Resting heart rate 50–70 bpm Detects the tachycardia seen with the injectable derivative
Intraocular pressure 10–18 mmHg The efficacy endpoint with the strongest supporting evidence
INR Individual target, typically 2.0–3.0 on warfarin Detects enzyme induction undoing anticoagulation
Free testosterone (men) Upper third of the age-adjusted laboratory range The specific fraction that rose in trial
Full blood count with calcium and uric acid No established functional target; track change from the individual's own baseline The exact indices that shifted in the women's trial
HDL cholesterol Above 55 mg/dL (men), above 65 mg/dL (women) Moved in the metabolic-syndrome trial, though in both arms

Cadence: Baseline set before starting; blood pressure daily through the first two weeks of titration; liver panel and INR at four and eight weeks; full panel plus the chosen efficacy marker at 12 weeks and every six months thereafter while use continues.

Qualitative Assessment

  • Stool frequency and consistency, the single most informative day-to-day signal, since diarrhoea is both the most common effect and the clearest dose marker
  • Light-headedness on standing, flushing, or palpitations, which point to the vasodilator effect
  • Waist circumference and clothing fit, more informative than scale weight given that trials found fat shifts without weight change
  • Sleep onset and night waking, given the stimulatory mechanism and the absence of trial data
  • Unexplained bruising, nosebleeds or prolonged bleeding from minor cuts, indicating platelet inhibition
  • Energy, appetite and hunger between meals, which trials assessed by questionnaire with mixed results
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.